Literature DB >> 9322850

Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas.

J Antinheimo1, H Haapasalo, M Haltia, M Tatagiba, S Thomas, A Brandis, M Sainio, O Carpen, M Samii, J Jääskeläinen.   

Abstract

The authors compared the histological appearance and proliferation potential of 35 meningiomas in patients with neurofibromatosis 2 (NF2) and 30 sporadic meningiomas in age- and gender-matched patients without NF2. The NF2 meningiomas showed more mitotic figures (p < 0.001) and nuclear pleomorphism (p = 0.003) than the sporadic meningiomas; however, the incidence of meningothelial, fibroblastic, and transitional subtypes occurred equally in both groups. The proliferation potential was significantly higher in the 35 meningiomas removed from 23 patients with NF2 than in the 30 sporadic meningiomas removed in the 30 patients without NF2 (mean MIB-1 labeling indices: 2.5 vs. 1.75, p = 0.0147). The higher proliferation potential of the NF2 meningiomas may reflect differences in molecular biology between sporadic and NF2 meningiomas and may be related to an earlier onset, multiplicity, and more aggressive behavior of NF2 tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322850     DOI: 10.3171/jns.1997.87.4.0610

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  20 in total

Review 1.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

Review 2.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

Review 3.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

4.  Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.

Authors:  Sayaka Yuzawa; Hiroshi Nishihara; Shigeru Yamaguchi; Hiromi Mohri; Lei Wang; Taichi Kimura; Masumi Tsuda; Mishie Tanino; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin; Norihiro Sato; Shinya Tanaka
Journal:  Mod Pathol       Date:  2016-04-22       Impact factor: 7.842

Review 5.  [Hereditary tumor syndromes in neuropathology].

Authors:  C Mawrin
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

Review 6.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

7.  Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features.

Authors:  Stéphane Goutagny; Alpha Boubacar Bah; Dominique Henin; Béatrice Parfait; Alexis Bozorg Grayeli; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

Review 8.  Meningiomas and neurofibromatosis.

Authors:  Stéphane Goutagny; Michel Kalamarides
Journal:  J Neurooncol       Date:  2010-08-17       Impact factor: 4.130

9.  Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoural oedema and other clinicoradiological and histological characteristics.

Authors:  Paulo Henrique Aguiar; Ana Maria Tsanaclis; Oswaldo Inácio Tella; José Pindaro Plese
Journal:  Neurosurg Rev       Date:  2003-04-08       Impact factor: 3.042

Review 10.  Advances in the treatment of neurofibromatosis-associated tumours.

Authors:  Andrew L Lin; David H Gutmann
Journal:  Nat Rev Clin Oncol       Date:  2013-08-13       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.